ArticleArchives of toxicology2026
Structure-activity relationship of synthetic cathinones: integrated in silico, in vitro, and in vivo studies of α-PiHP analogues.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic cathinones represent the main group of emerging psychostimulants consumed worldwide. Structural modifications of these compounds have led to pyrovalerones, potent dopamine transporter (DAT) inhibitors associated with high abuse liability. Among them, α-pyrrolidinoisohexanophenone (α-PiHP) became the most seized pyrovalerone in the European Union in 2023. Novel analogues have rapidly appeared, yet their neuropharmacological and toxicological properties remain unknown. This study aimed to characterize α-PiHP and five structurally related derivatives (3-Me-α-PiHP, 4-Me-α-PiHP, 3-F-α-PiHP, 4-F-α-PiHP, and MDPiHP). Monoamine transporter activity was evaluated using HEK293 cells expressing human norepinephrine (hNET), hDAT, or serotonin (hSERT) transporters through uptake inhibition and binding assays. Molecular docking was performed to model interactions at hDAT. Psychostimulant, thigmotactic, and rewarding effects were evaluated in male Swiss CD-1 mice using horizontal locomotor activity, open field, and conditioned place preference paradigms. Lethality after drug administration was also assessed. All compounds potently inhibited hDAT and hNET, while displaying limited activity at hSERT. This resulted in high hDAT/hSERT ratios indicative of a stimulant-like profile and elevated abuse liability, confirmed in vivo by pronounced psychostimulant and rewarding effects. All molecules interacted with the orthosteric binding site at hDAT and displayed higher binding affinity than cocaine in in vitro and in silico studies. Meta-substituted analogues showed greater hDAT affinity and behavioural responses than para-isomers. Notably, MDPiHP exhibited the highest potency and affinity, strongest psychostimulant effects and significant lethality. These findings demonstrate that minor structural modifications markedly influence pharmacological activity of pyrovalerone derivatives, highlighting the high abuse potential and health risks associated with emerging α-PiHP analogues.
Indexed as
Identifiers
42362749What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.